Pancreatic Cancer Research

ResearcherThe Cancer Institute HospitalActive in the last 2 years

Takashi Sasaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7109-9835; OpenAlex author ID A5050881417, A5129780883. Sources: OpenAlex.

Their work

Papers
60 (first author 23, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
107
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 3 papers · 2020: 6 papers · 2021: 9 papers · 2022: 9 papers · 2023: 11 papers · 2024: 4 papers · 2025: 5 papers · 2026: 7 papers

Papers 50 of 60

  1. Endoscopic Retrograde Cholangiopancreatography-guided Biliary Drainage with Duckbill-type Anti-reflux Metal Stent versus Endoscopic Ultrasound-guided Hepaticog… First author DOI 10.1002/deo2.70154↗
  2. Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy. Co-author DOI 10.1002/jhbp.70058↗
  3. Changing treatment outcomes in metastatic and recurrent pancreatic cancer: a real-world comparison before and after the availability of nanoliposomal irinoteca… Co-author DOI 10.1093/jjco/hyaf194↗
  4. Gastrointestinal Bleeding after Particle Radiotherapy for Pancreatic Cancer. Co-author DOI 10.1159/000550483↗
  5. Patient-derived orthotopic xenograft models recapitulate the peritoneal dissemination of pancreatic cancer and delineate its transcriptional and regulatory pro… Co-author DOI 10.1186/s13046-026-03668-9↗
  6. Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. Co-author DOI 10.1245/s10434-025-18806-4↗
  7. ASO Visual Abstract: Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. Co-author DOI 10.1245/s10434-025-19046-2↗
  8. Clinical implications of disappearing pancreatic cancer liver metastases: Lessons from colorectal liver metastases. Co-author DOI 10.1016/j.ejso.2025.109635↗
  9. Clinical predictors of KRAS mutation detection in liquid biopsies for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2025.06.013↗
  10. Impact of Statin Use on Survival in Patients With Unresectable Pancreatic cancer Receiving Gemcitabine Plus Nab-Paclitaxel: A Multicenter Retrospective Study. Co-author DOI 10.1097/mpa.0000000000002411↗
  11. [Multidisciplinary treatment for borderline resectable pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.122.810↗
  12. Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with a Poor Performance Status. First author DOI 10.2169/internalmedicine.3577-24↗
  13. Outcomes of 6-mm diameter fully covered self-expandable metal stents for preoperative biliary drainage in pancreatic cancer. Co-author DOI 10.1002/deo2.360↗
  14. Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.10.001↗
  15. A proposal of ABCD metastasectomy criteria for synchronous/metachronous metastatic pancreatic cancer in the era of multidisciplinary treatment. Co-author DOI 10.1093/bjs/znad417↗
  16. Bone loss over time and risk of osteoporosis in advanced pancreatic cancer. First author DOI 10.1093/jjco/hyae028↗
  17. The efficacy and safety of a duckbill-type anti-reflux metal stent as the initial metal stent for distal malignant biliary obstruction in unresectable pancreat… First author DOI 10.1002/deo2.205↗
  18. Outcomes of pancreatic cancer with liver oligometastasis. First author DOI 10.1002/jhbp.1184↗
  19. Long-term outcomes of duckbill-type anti-reflux metal stents versus conventional covered metal stents in reinterventions after covered biliary metal stent dysf… First author DOI 10.1007/s00464-022-09836-0↗
  20. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with e… Co-author DOI 10.1016/j.hpb.2022.09.012↗
  21. Prognostic impact of osteosarcopenia in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel. First author DOI 10.1016/j.pan.2023.02.002↗
  22. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  23. Outcomes of lung oligometastasis in pancreatic cancer. First author DOI 10.1093/jjco/hyad111↗
  24. Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005395↗
  25. Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery. Co-author DOI 10.1245/s10434-023-13534-z↗
  26. Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia. First author DOI 10.2169/internalmedicine.0730-22↗
  27. Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic C… First author DOI 10.3390/cancers15020358↗
  28. Early-onset pancreatic cancer: Clinical characteristics and survival outcomes. First author DOI 10.1016/j.pan.2022.04.003↗
  29. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer. First author DOI 10.1093/jjco/hyac145↗
  30. Removal of a biliary self-expandable metal stent using the zipline technique for pancreatic cancer with duodenal stricture. Co-author DOI 10.1111/den.14190↗
  31. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOL… Co-author DOI 10.1245/s10434-022-11503-6↗
  32. ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcit… Co-author DOI 10.1245/s10434-022-11621-1↗
  33. Impact of the COVID-19 Pandemic on the Management and End-of-life Care of Unresectable Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.0492-22↗
  34. Multiple Gastric Metastases after Distal Pancreatectomy for Pancreatic Cancer. First author DOI 10.2169/internalmedicine.8848-21↗
  35. CA19-9 Reduction After 4 Months of Treatment Is a Prognostic Factor for Locally Advanced Pancreatic Cancer. Co-author DOI 10.21873/invivo.13024↗
  36. Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. Co-author DOI 10.3390/ijms23031205↗
  37. Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients. First author DOI 10.1007/s10147-020-01827-2↗
  38. The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy. First author DOI 10.1007/s10147-021-01912-0↗
  39. A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma. First author DOI 10.1007/s12328-021-01480-w↗
  40. Improved prognosis of pancreatic cancer patients with peritoneal metastasis. First author DOI 10.1016/j.pan.2021.03.006↗
  41. The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer. First author DOI 10.1093/jjco/hyaa247↗
  42. The prognostic impact of tumour location and first-line chemotherapy regimen in locally advanced pancreatic cancer. First author DOI 10.1093/jjco/hyab014↗
  43. Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer. First author DOI 10.1093/jjco/hyab091↗
  44. Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancre… First author DOI 10.1097/mpa.0000000000001801↗
  45. CT Abnormalities of the Pancreas Associated With the Subsequent Diagnosis of Clinical Stage I Pancreatic Ductal Adenocarcinoma More Than 1 Year Later: A Case-C… Co-author DOI 10.2214/ajr.21.26014↗
  46. Comprehensive comparison of clinicopathological characteristics, treatment, and prognosis of borderline resectable pancreatic cancer according to tumor locatio… First author DOI 10.1016/j.pan.2020.07.004↗
  47. Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. Co-author DOI 10.1038/s41467-020-16711-w↗
  48. Novel risk factors for recurrent biliary obstruction and pancreatitis after metallic stent placement in pancreatic cancer. First author DOI 10.1055/a-1244-1989↗
  49. A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001484↗
  50. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. Co-author DOI 10.1186/s12885-020-06945-8↗

Closest collaborators

The 25 strongest of 107 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Naoki Sasahira · 56 shared papers, 2011–2026 · strength 8.84
  2. Masato Ozaka · 48 shared papers, 2018–2026 · strength 8.11
  3. Tsuyoshi Takeda · 39 shared papers, 2019–2026 · strength 6.54
  4. Takafumi Mie · 34 shared papers, 2020–2026 · strength 5.62
  5. Takaaki Furukawa · 31 shared papers, 2020–2026 · strength 5.13
  6. Takeshi Okamoto · 24 shared papers, 2021–2026 · strength 4.42
  7. Akiyoshi Kasuga · 27 shared papers, 2020–2025 · strength 3.97
  8. Masato Matsuyama · 25 shared papers, 2019–2023 · strength 3.42
  9. Yu Takahashi · 16 shared papers, 2020–2026 · strength 2.61
  10. Yuto Yamada · 16 shared papers, 2020–2023 · strength 2.14
  11. Atsushi Oba · 12 shared papers, 2022–2026 · strength 2.06
  12. Yoshihiro Ono · 11 shared papers, 2021–2026 · strength 1.89
  13. Yosuke Inoue · 11 shared papers, 2020–2026 · strength 1.84
  14. Hiromichi Ito · 8 shared papers, 2022–2026 · strength 1.38
  15. Hiroki Nakagawa · 7 shared papers, 2022–2025 · strength 1.25
  16. Aya Maekawa · 6 shared papers, 2023–2026 · strength 1.14
  17. Akio Saiura · 7 shared papers, 2020–2024 · strength 1.05
  18. Yosuke Inoue · 5 shared papers, 2023–2026 · strength 0.92
  19. Manabu Takamatsu · 5 shared papers, 2021–2026 · strength 0.83
  20. Kojiro Omiya · 4 shared papers, 2023–2025 · strength 0.69
  21. Yukari Suzuki · 2 shared papers, 2026 · strength 0.54
  22. Jun Hamada · 2 shared papers, 2026 · strength 0.53
  23. Hiroyuki Isayama · 8 shared papers, 2011–2025 · strength 0.53
  24. Yousuke Nakai · 8 shared papers, 2011–2025 · strength 0.53
  25. Yuki Hirose · 3 shared papers, 2024–2025 · strength 0.53

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.